GSK

“Raised $263m in combined Series D and E funding from backers like RA Capital Management, GV, GSK, Bill Gates, and Jeff Bezos.”

“GSK agreed to acquire Nuvalent, a developer of lung cancer treatments, for $10.6 billion.”

“GSK agreed to buy cancer drug developer Nuvalent for $10.6b in cash, or $124 per share (a 40% premium to yesterday's closing price).”